Exelead is a CDMO dedicated to the development and commercialization of therapeutics to treat life-threatening diseases. Exelead’s core technologies focus on the manufacture of sterile drug products specializing in liposomal and PEGylation formulation technologies. Exelead has development capabilities that can be utilized to improve drug delivery and drug product characterization. The Indianapolis, Indiana manufacturing facility produces proprietary parenteral pharmaceuticals for oncology and enzyme replacement treatment, as well as for the treatment of numerous infectious diseases. Our staff is a balance of: chemists, chemical engineers, microbiologists, and pharmaceutical manufacturing experts. Senior Exelead management is a mix of seasoned executives from the pharmaceutical and biotechnology industries. Exelead is a wholly owned subsidiary of Essetefin SpA (Rome, Italy) and is led by John Rigg, Vice President and General Manager.